November 16, 2014 | The Israeli clinical stage pharmaceutical company that develops drugs to treat nervous system disorders, NeuroDerm, raised $45 million in a NASDAQ IPO. This is down from estimates assessing that NeuroDerm would raise between $60-82 million in the IPO. However, NeuroDerm began selling his 4,500,000 shares at $10.00 a share. Jefferies LLC and Cowen and Company are the book-running managers for the offering, along with Oppenheimer & Co. and Roth Capital Partners. NeuroDerm has its headquarters in Rehovot, Israel.